STAT+: Closely watched Pfizer lung cancer drug falls short in clinical trial

AI Summary

Pfizer announced that its experimental lung cancer drug did not meet expectations in a clinical trial, falling short of replacing a widely used chemotherapy treatment. The outcome impacts Pfizer's oncology drug pipeline and future market prospects.

Pfizer said an experimental drug it hoped could replace a widely used chemotherapy in one of the most common forms of lung cancer fell short in a clinical trial.